YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Leading industry experts will come together for multi-day conference to discuss how advancements in AI-driven automation, agentic AI, and data analytics will accelerate clinical trials BOSTON, October 08, 2026--(BUSINESS WIRE)--eClinical S…
Merck MRK announced that the FDA has expanded the label of its oral cancer drug Welireg (belzutifan) for a third indication in advanced renal cell carcinoma (RCC), the most common type of adult kidney cancer. The drug has been approved in…
Biogen BIIB has been undergoing a major transformation. The company has long been seeing declining sales of its key multiple sclerosis ("MS") due to generic competition for Tecfidera globally, biosimilar competition for Tysabri in Europe a…
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer's disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improv…
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new r…
Allarity Therapeutics, Inc. TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a…
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligibl…
Biogen Inc. The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd…
Biogen Inc. An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada's Drug A…
Recommendation advances equitable access discussions for eligible Canadians and highlights the urgency of timely reimbursement, as Alzheimer's disease progression does not wait MISSISSAUGA, ON and TORONTO, Aug. 27, 2026 /CNW/ -- Eisai Limi…
Company Logo The global indocyanine green (ICG) market was valued at USD 180 million in 2025 and is projected to reach USD 380 million by 2031, growing at a 13.26% CAGR. Growth is driven by fluorescence-guided surgery, minimally invasive p…
Eisai (TSE:4523) is back in focus after announcing that once weekly LEQEMBI IQLIK subcutaneous injections for early Alzheimer's disease are now available in the U.S., offering an at home alternative to intravenous treatment. Over the past…
Forward Deployed Engineers (FDE's) turn AI initiatives into governed, measurable production systems. ISSAQUAH, Wash., Aug. 27, 2026 /PRNewswire/ -- Sophus IT Solutions (https://www.linkedin.com/company/sophusitsolutions), an AI native engi…
New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to M…
STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, n…
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc.…
[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults w…
Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in un…
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter. Continue Reading
STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's seco…
BOSTON and TOKYO, July 28, 2026 /PRNewswire/ -- CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co…
Canada's Drug Agency recognizes the clinical value of LEQEMBI®in slowing Alzheimer's progression and helping keep patients in earlier stages of disease for longer MISSISSAUGA, ON and TORONTO, July 16, 2026 /CNW/ -- Eisai Limited ("Eisai")…
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months. Continue Reading
Biogen Inc. Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 (GLOBE N…
Eisai and Biogen recently received FDA approval for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector initiation dose that allows adults with early Alzheimer's disease to start and continue treatment at home instead of relying solely…
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a o…
[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images * The US FDA has approved Biogen (BIIB [https://seekingalpha.com/symbol/BIIB]) and Eisai's (ESALF [https://seekingalpha.com/symbol/ESALF]) (ESAIY [https://seekingalpha…
Biogen Inc. LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 202…
Nuvation Bio Inc (NYSE:NUVB) is one of billionaire David Abrams' top stock picks with upside potential. Nuvation Bio shares gained nearly 170% over the past year, and analysts project a more than 150% upside for the stock over the next 12…
Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug's future clinical development TOKYO, Jul…
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating…
Biogen Inc. New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOB…
In late June 2026, Nuvation Bio announced that partner Eisai's Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer was validated by the U.K. MHRA under the International Recognition Pr…
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC…
Biogen BIIB is in the midst of a major portfolio transition. The company is seeing declining sales of its key multiple sclerosis ("MS") drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, due to generic…
-- $135 million equity financing with participation from leading specialist investors, corporate investors, and long-term growth partners, including Wellington Partners, JIC Venture Growth Investments (JIC VGI), Founders Fund, Narya Capita…